GB2386836B - Anti-cancer combinations - Google Patents

Anti-cancer combinations

Info

Publication number
GB2386836B
GB2386836B GB0206839A GB0206839A GB2386836B GB 2386836 B GB2386836 B GB 2386836B GB 0206839 A GB0206839 A GB 0206839A GB 0206839 A GB0206839 A GB 0206839A GB 2386836 B GB2386836 B GB 2386836B
Authority
GB
United Kingdom
Prior art keywords
anti
cancer
combinations
cancer combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB0206839A
Other versions
GB2386836A (en
GB0206839D0 (en
Inventor
Liang-Chuan Steve Wang
James William Paxton
Lai-Ming Ching
Bruce Charles Baguley
Philip Kestell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Ventures Ltd
Cancer Research Technology Ltd
Original Assignee
Cancer Research Ventures Ltd
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Ventures Ltd, Cancer Research Technology Ltd filed Critical Cancer Research Ventures Ltd
Priority to GB0206839A priority Critical patent/GB2386836B/en
Publication of GB0206839D0 publication Critical patent/GB0206839D0/en
Publication of GB2386836A publication Critical patent/GB2386836A/en
Application granted granted Critical
Publication of GB2386836B publication Critical patent/GB2386836B/en
Application status is Expired - Fee Related legal-status Critical
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
GB0206839A 2002-03-22 2002-03-22 Anti-cancer combinations Expired - Fee Related GB2386836B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0206839A GB2386836B (en) 2002-03-22 2002-03-22 Anti-cancer combinations

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0206839A GB2386836B (en) 2002-03-22 2002-03-22 Anti-cancer combinations
PCT/GB2003/001320 WO2003080044A1 (en) 2002-03-22 2003-03-20 Anti-cancer combinations of dmxaa and a nsaid
JP2003577872A JP2005526786A (en) 2002-03-22 2003-03-20 Anti-cancer combination of Dmxaa and nsaid
AU2003217035A AU2003217035A1 (en) 2002-03-22 2003-03-20 Anti-cancer combinations of dmxaa and a nsaid
EP20030712423 EP1487433A1 (en) 2002-03-22 2003-03-20 Anti-cancer combinations of dmxaa and a nsaid
US10/946,833 US7462642B2 (en) 2002-03-22 2004-09-22 Anti-cancer combinations
US12/264,197 US20090062377A1 (en) 2002-03-22 2008-11-03 Anti-cancer combinations

Publications (3)

Publication Number Publication Date
GB0206839D0 GB0206839D0 (en) 2002-05-01
GB2386836A GB2386836A (en) 2003-10-01
GB2386836B true GB2386836B (en) 2006-07-26

Family

ID=9933545

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0206839A Expired - Fee Related GB2386836B (en) 2002-03-22 2002-03-22 Anti-cancer combinations

Country Status (6)

Country Link
US (2) US7462642B2 (en)
EP (1) EP1487433A1 (en)
JP (1) JP2005526786A (en)
AU (1) AU2003217035A1 (en)
GB (1) GB2386836B (en)
WO (1) WO2003080044A1 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60027719T2 (en) * 1999-06-14 2007-04-26 Cancer Research Technology Ltd. cancer therapy
AU8271701A (en) 2000-07-28 2002-02-13 Cancer Res Ventures Ltd Cancer treatment by combination therapy
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations
WO2005077394A1 (en) * 2004-02-11 2005-08-25 Ramot At Tel-Aviv University Ltd Compositions for treatment of cancer and inflammation with curcumin and at least one nsaid
US20100297112A1 (en) * 2005-08-26 2010-11-25 Antisoma Research Limited Combinations comprising dmxaa for the treatment of cancer
WO2007087113A2 (en) 2005-12-28 2007-08-02 The Scripps Research Institute Natural antisense and non-coding rna transcripts as drug targets
RU2604489C2 (en) 2008-10-03 2016-12-10 КьюРНА,Инк.,US Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
EP2370581B1 (en) 2008-12-04 2016-08-03 CuRNA, Inc. Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
JP6091752B2 (en) 2008-12-04 2017-03-08 クルナ・インコーポレーテッド Treatment of native erythropoietin by suppressing the antisense transcript (epo) related diseases for Epo
US9074210B2 (en) 2009-02-12 2015-07-07 Curna, Inc. Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF
CA2755409A1 (en) 2009-03-16 2010-09-23 Joseph Collard Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
CN102549159B (en) 2009-03-17 2016-08-10 库尔纳公司 By suppressing natural antisense transcript for the δ-like 1 homolog (DLK1) treating a disease associated DLK1
ES2609655T3 (en) 2009-05-06 2017-04-21 Curna, Inc. Treatment related tristetraprolina (TTP) diseases by inhibiting natural antisense transcript for TTP
JP5883782B2 (en) 2009-05-06 2016-03-15 クルナ・インコーポレーテッド Treatment of lipid transport metabolic gene associated disease by suppressing the natural antisense transcript on lipid transport metabolism genes
ES2618572T3 (en) 2009-05-08 2017-06-21 Curna, Inc. Treatment related to the family of dystrophin diseases by inhibiting a natural antisense transcript for the family of dmd
CA2762369A1 (en) 2009-05-18 2010-11-25 Joseph Collard Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
CN102549158B (en) 2009-05-22 2017-09-26 库尔纳公司 By inhibiting transcription factor for e3 (tfe3) natural antisense transcript treating TFE3 protein and insulin receptor substrate 2 (irs2) related diseases
US8791085B2 (en) 2009-05-28 2014-07-29 Curna, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
ES2629339T3 (en) 2009-06-16 2017-08-08 Curna, Inc. Treatment related Paraoxonase1 (PON1) diseases by inhibiting natural antisense transcript to PON1
US8859515B2 (en) 2009-06-24 2014-10-14 Curna, Inc. Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2
CN102482672B (en) 2009-06-26 2016-11-09 库尔纳公司 By suppressing natural antisense transcript Down's syndrome gene therapy Down's syndrome gene-related diseases
WO2011017516A2 (en) 2009-08-05 2011-02-10 Curna, Inc. Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
CN102625841A (en) 2009-08-11 2012-08-01 欧科库尔纳有限责任公司 Treatment of Adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an Adiponectin (ADIPOQ)
WO2011022606A2 (en) 2009-08-21 2011-02-24 Curna, Inc. Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
WO2011031482A2 (en) 2009-08-25 2011-03-17 Curna, Inc. Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
WO2011022782A1 (en) * 2009-08-27 2011-03-03 Medvet Science Pty Ltd Combinations comprising imatinib mesylate and diclofenac
US20120295952A1 (en) 2009-09-25 2012-11-22 Curna, Inc. Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
ES2661813T3 (en) 2009-12-16 2018-04-04 Curna, Inc. Treatment related transcription factor peptidase membrane, site 1 (mbtps1) by inhibiting the natural antisense transcript to mbtps1 gene diseases
US9068183B2 (en) 2009-12-23 2015-06-30 Curna, Inc. Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
DK2516648T3 (en) 2009-12-23 2018-02-12 Curna Inc Treatment of hepatocytvækstfaktor- (HGF) related diseases by inhibition of the natural antisense transcript against HGF
CN102770540B (en) 2009-12-29 2017-06-23 库尔纳公司 63 is by inhibiting tumor protein (p63) of a natural antisense transcript treating p63 associated diseases
CN102782134B (en) 2009-12-29 2017-11-24 库尔纳公司 By inhibiting NRF 1 (nrf1) natural antisense transcripts treating related diseases NRF1
CN102791862B (en) 2009-12-31 2017-04-05 库尔纳公司 By inhibiting insulin receptor substrate 2 (irs2) and transcription factor e3 (tfe3) natural antisense transcripts treating related diseases IRS2
DK2521784T3 (en) 2010-01-04 2018-03-12 Curna Inc Treatment of interferon regulatory factor 8- (irf8) related diseases by inhibition of the natural antisense transcript against irf8
RU2612161C2 (en) 2010-01-06 2017-03-02 Курна, Инк. Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to pancreatic developmental gene
CA2786535C (en) 2010-01-11 2019-03-26 Curna, Inc. Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
KR101853510B1 (en) 2010-01-25 2018-06-20 큐알엔에이, 인크. Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
WO2011103528A2 (en) 2010-02-22 2011-08-25 Opko Curna Llc Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
EP2553098B1 (en) 2010-04-02 2017-10-11 CuRNA, Inc. Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
RU2610661C2 (en) 2010-04-09 2017-02-14 Курна, Инк. Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
CN107988228A (en) 2010-05-03 2018-05-04 库尔纳公司 Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to sirtuin (sirt)
TWI531370B (en) 2010-05-14 2016-05-01 Curna Inc Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
EP2576784B1 (en) 2010-05-26 2017-11-15 CuRNA, Inc. Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
CA2799207C (en) 2010-05-26 2019-03-26 Curna, Inc. Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
JP6023705B2 (en) 2010-06-23 2016-11-09 カッパーアールエヌエー,インコーポレイテッド Treatment of sodium channel, voltage-dependent, SCNA related diseases by inhibition of the natural antisense transcripts for α-subunit (SCNA)
US8980860B2 (en) 2010-07-14 2015-03-17 Curna, Inc. Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG
RU2624048C2 (en) 2010-10-06 2017-06-30 Курна, Инк. Treatment of diseases associated with the sialidase 4 (neu4) gene, by gene neu4 natural antisense transcript inhibition
CN103180445B (en) 2010-10-22 2018-02-16 库尔纳公司 By inhibiting α-L- iduronic acid enzyme (IDUA) natural antisense transcripts treating related diseases IDUA
US10000752B2 (en) 2010-11-18 2018-06-19 Curna, Inc. Antagonat compositions and methods of use
CA2818824A1 (en) 2010-11-23 2012-05-31 Joseph Collard Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
WO2012167028A2 (en) * 2011-06-02 2012-12-06 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition
CA2838588A1 (en) 2011-06-09 2012-12-13 Curna, Inc. Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
DK2793874T3 (en) 2011-12-20 2017-02-06 Ectin Res Ab Synergistic kombinaton containing avermectins and an NSAID for tumor inhibition
EP2825648B1 (en) 2012-03-15 2018-09-05 CuRNA, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655470A (en) 1969-03-29 1972-04-11 Toa Gosei Chem Ind Process for the production of a foamed thermoplastic resin sheet
DE2015265A1 (en) 1969-03-29 1970-10-08
FR2516922B1 (en) * 1981-11-25 1984-02-10 Lipha
IL77133A (en) 1984-12-04 1991-01-31 Lilly Co Eli Antineoplastic pharmaceutical compositions containing pentofuranoside derivatives,some new such compounds and their preparation
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
DE3789299T2 (en) 1986-12-23 1994-08-04 Warner Lambert Co Compounds with anti-tumor and anti-bacterial properties.
US5281620A (en) 1986-12-23 1994-01-25 Cancer Research Campaign Technology Limited Compounds having antitumor and antibacterial properties
JPH01193227A (en) 1988-01-29 1989-08-03 Green Cross Corp:The Adjuvant for cancer immunotherapy
US5126129A (en) 1988-05-23 1992-06-30 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Cancer therapy using interleukin-2 and flavone compounds
US5075287A (en) 1989-03-03 1991-12-24 Nisshin Oil Mills, Inc. Muramyl peptide derivatives and immunoregulating compositions containing them
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
US5250296A (en) 1990-11-29 1993-10-05 Takeda Chemical Industries, Ltd. Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
EP0551200A1 (en) 1992-01-07 1993-07-14 National University Of Singapore Protein phosphatase inhibitors for use in therapy
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
GB9308166D0 (en) 1993-04-20 1993-06-02 Cancer Res Campaign Tech Cancer therapy
GB9320484D0 (en) 1993-10-05 1993-11-24 Wellcome Found Pharmaceutical combinations
US5620875A (en) 1995-02-17 1997-04-15 University Of Portland Transfer of taxol from yew tree cuttings into a culture medium over time
AU5688596A (en) 1995-04-13 1996-10-30 Deutsche Om Arzneimittel Gmbh Anti-cd14 antibodies for use in the induction of il-10 secre tion
EP0743064A1 (en) 1995-05-17 1996-11-20 Eli Lilly And Company Leukotriene antagonists for use in the treatment or prevention of alzheimer's disease
JPH0940690A (en) 1995-05-23 1997-02-10 Kitarou Oka Steroid glycoside and medicine containing the same as active ingredient
WO1997004761A1 (en) 1995-07-28 1997-02-13 Trustees Of Boston University Methods and compositions for treating cell proliferative disorders
US5977077A (en) 1995-08-28 1999-11-02 Interlab Corporation Xanthone analogs for the treatment of infectious diseases
US5863904A (en) 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
WO1998025600A1 (en) 1996-12-13 1998-06-18 Eli Lilly And Company Leukotriene antagonists for treatment or inhibition of gout
AU726215B2 (en) 1996-12-13 2000-11-02 Eli Lilly And Company Leukotriene antagonists for oral squamous cell carcinoma
CA2274908A1 (en) 1996-12-13 1998-06-18 Eli Lilly And Company Leukotriene antagonists for cerebral focal stroke
US5998454A (en) 1997-03-21 1999-12-07 Eli Lilly And Company Leukotriene antagonists useful for treating iritis
US5910505A (en) 1997-03-21 1999-06-08 Eli Lilly And Company Leukotriene antagonists for use in the treatment or inhibition of oral squamous cell carcinoma
WO1998042345A1 (en) 1997-03-21 1998-10-01 Eli Lilly And Company Leukotriene antagonists useful for treating cerebral focal stroke
US5914340A (en) 1997-03-21 1999-06-22 Eli Lilly And Company Leukotriene antagonists useful for treating dermatoses
AU6572298A (en) 1997-03-21 1998-10-20 Eli Lilly And Company Leukotriene antagonists useful for treating ischemia reperfusion injury
WO1998042335A1 (en) 1997-03-21 1998-10-01 Eli Lilly And Company Leukotriene antagonists useful for treating gout
WO1998042336A1 (en) 1997-03-21 1998-10-01 Eli Lilly And Company Leukotriene antagonists useful for treating gingivitis
AU6764798A (en) 1997-03-21 1998-10-20 Eli Lilly And Company Leukotriene antagonists useful for treating cystic fibrosis
DE19721211A1 (en) 1997-05-21 1998-11-26 Lindner Sen Wolfgang Dr Med Three-fold treatment of tumours providing synergistic effect
CN1217698C (en) 1998-08-24 2005-09-07 马克西姆药品公司 Activation and protection of T-cells (CD4+ and CD8+) using and H2 receptor agonist and other T-cell activating agents
AUPP609198A0 (en) 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
US6174873B1 (en) 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
GB9903404D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
PT1033364E (en) 1999-03-01 2005-07-29 Pfizer Prod Inc Cyan with oxamic acids and derivatives thereof as thyroid receptor ligands
DE60027719T2 (en) 1999-06-14 2007-04-26 Cancer Research Technology Ltd. cancer therapy
US6806257B1 (en) 1999-10-20 2004-10-19 Board Of Trustees Of Southern Illinois University Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators
EP1231938A2 (en) 1999-11-11 2002-08-21 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
AU1916601A (en) 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
EP1231939A2 (en) 1999-11-11 2002-08-21 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
AU1916501A (en) 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
JP2003522790A (en) 2000-02-17 2003-07-29 メルク エンド カムパニー インコーポレーテッド Treatment or prevention of prostate cancer using Cox-2 selective inhibitor
JP2001247459A (en) 2000-03-03 2001-09-11 Oakland Uniservices Ltd Combination therapy for cancer
AU8271701A (en) 2000-07-28 2002-02-13 Cancer Res Ventures Ltd Cancer treatment by combination therapy
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
GB0321999D0 (en) 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations
GB0517387D0 (en) 2005-08-26 2005-10-05 Antisoma Res Ltd Combinations for the treatment of cancer
US20100297112A1 (en) 2005-08-26 2010-11-25 Antisoma Research Limited Combinations comprising dmxaa for the treatment of cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Cancer Chemother Pharmacol, 47, 2001, Zhou et al, pp. 319-326. *
Cancer Chemother Pharmacol, 47, 2001, Zhou et al, pp. 541-544. *
Cancer Research, 57, 1997, Miners et al, pp. 284-289. *
Pharmacy and Pharmacology, 53, 2001, Zhou et al, pp. 463-471. *

Also Published As

Publication number Publication date
US20050131059A1 (en) 2005-06-16
GB2386836A (en) 2003-10-01
GB0206839D0 (en) 2002-05-01
AU2003217035A1 (en) 2003-10-08
US7462642B2 (en) 2008-12-09
JP2005526786A (en) 2005-09-08
US20090062377A1 (en) 2009-03-05
EP1487433A1 (en) 2004-12-22
WO2003080044A1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
TWI372050B (en) (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
TWI315196B (en) Zwischenwirbelimplantat
TWI333416B (en) Zwischenwirbelimplantat
TWI329506B (en) Knochenplatte
TWI337072B (en) Knochenplatte
TWI375796B (en) Immuno-amplification
TWI333182B (en) Optisches sicherheitselement
TWI328438B (en) Klemmvorrichtung
TWI312049B (en) Flammendurchschlagsicherung
TWI349540B (en) Gelenkendoprothese
GB0322140D0 (en) Combinations
DE602004030992D1 (en) Wirbelstangen-approximator
DE602004026407D1 (en) Histondeacetylase-hemmer
DE602004026619D1 (en) N-substituierte p-menthancarbonsäureamide
DE602004027618D1 (en) Mobil-ethernet
DE502004007735D1 (en) Flächiges implantat
DE602004027011D1 (en) Uziervorrichtung
DE502004011703D1 (en) N-heterocyclyl-phenylsubstituierte cyclische ketoenole
ZA200507562B (en) HIV-peptide-carrier-conjugates
DE602004021472D1 (en) Pyrimiidinverbindungen
DE602004026918D1 (en) Adaptives fec-codewort-management
DE602004023924D1 (en) Ease-hemmer
DE602004029242D1 (en) Pyrazolamidverbindungen
DE602004019681D1 (en) Tibiaknieprothese
DE602004008468D1 (en) Photoresistpolymerzusammensetzungen

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: CANCER RESEARCH TECHNOLOGY LIMITED

Free format text: FORMER APPLICANT(S): CANCER RESEARCH VENTURES LIMITED

PCNP Patent ceased through non-payment of renewal fee

Effective date: 20110322